Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

25/07/2025 13:59

Kiniksa Pharmaceuticals International PLC KNSA.OQ KNSA.O is expected to  show a rise in quarterly revenue when it reports  results on July 29 for the period ending June 30 2025

The London United Kingdom-based   company is expected to report a 40.5% increase in revenue to $145.218 million from $103.39 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals International PLC is for earnings of 18 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International PLC is $40.00, about 32.8% above its last closing price of $26.90

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.01
0.04
0.11
Beat
161.9
Dec. 31 2025
-0.10
0.00
-0.12
Missed
-5,900
Sep. 30 2024
-0.02
0.03
-0.18
Missed
-662.5​
Jun. 30 2024
-0.07
-0.07
-0.06
Beat
20
​​Mar. 31 2024
-0.16
-0.16
-0.25
Missed
-53.1
Dec. 31 2023
-0.12
-0.14
0.35
Beat
350​
Sep. 30 2023
-0.17
-0.17
-0.20
Missed
-19.4
Jun. 30 2023
-0.17
-0.17
0.21
Beat
225.4

This summary was machine generated July 25 at 12:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)